Cargando…

Advances in Computational Polypharmacology

In drug discovery, polypharmacology encompasses the use of small molecules with defined multi‐target activity and in vivo effects resulting from multi‐target engagement. Multi‐target compounds are often efficacious in the treatment of complex diseases involving target and pathway networks, but might...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldmann, Christian, Bajorath, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078381/
https://www.ncbi.nlm.nih.gov/pubmed/36002382
http://dx.doi.org/10.1002/minf.202200190
_version_ 1785020505552584704
author Feldmann, Christian
Bajorath, Jürgen
author_facet Feldmann, Christian
Bajorath, Jürgen
author_sort Feldmann, Christian
collection PubMed
description In drug discovery, polypharmacology encompasses the use of small molecules with defined multi‐target activity and in vivo effects resulting from multi‐target engagement. Multi‐target compounds are often efficacious in the treatment of complex diseases involving target and pathway networks, but might also elicit unwanted side effects. Computational approaches such as target prediction or multi‐target ligand design have been used to support polypharmacological drug discovery. In addition to efforts directed at the identification or design of new multi‐target compounds, other computational investigations have aimed to differentiate such compounds from potential false‐positives or explore the molecular basis of multi‐target activities. Herein, a concise overview of the field is provided and recent advances in computational polypharmacology through machine learning are discussed.
format Online
Article
Text
id pubmed-10078381
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100783812023-04-07 Advances in Computational Polypharmacology Feldmann, Christian Bajorath, Jürgen Mol Inform Minireviews In drug discovery, polypharmacology encompasses the use of small molecules with defined multi‐target activity and in vivo effects resulting from multi‐target engagement. Multi‐target compounds are often efficacious in the treatment of complex diseases involving target and pathway networks, but might also elicit unwanted side effects. Computational approaches such as target prediction or multi‐target ligand design have been used to support polypharmacological drug discovery. In addition to efforts directed at the identification or design of new multi‐target compounds, other computational investigations have aimed to differentiate such compounds from potential false‐positives or explore the molecular basis of multi‐target activities. Herein, a concise overview of the field is provided and recent advances in computational polypharmacology through machine learning are discussed. John Wiley and Sons Inc. 2022-09-06 2022-12 /pmc/articles/PMC10078381/ /pubmed/36002382 http://dx.doi.org/10.1002/minf.202200190 Text en © 2022 The Authors. Molecular Informatics published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Minireviews
Feldmann, Christian
Bajorath, Jürgen
Advances in Computational Polypharmacology
title Advances in Computational Polypharmacology
title_full Advances in Computational Polypharmacology
title_fullStr Advances in Computational Polypharmacology
title_full_unstemmed Advances in Computational Polypharmacology
title_short Advances in Computational Polypharmacology
title_sort advances in computational polypharmacology
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078381/
https://www.ncbi.nlm.nih.gov/pubmed/36002382
http://dx.doi.org/10.1002/minf.202200190
work_keys_str_mv AT feldmannchristian advancesincomputationalpolypharmacology
AT bajorathjurgen advancesincomputationalpolypharmacology